Video

Dr. Agarwal on Unmet Needs in mHSPC

Neeraj Agarwal, MD, discusses unmet needs in metastatic hormone-sensitive prostate cancer.

Neeraj Agarwal, MD, professor of medicine, and director of the Genitourinary Oncology Program, Huntsman Cancer Institute, discusses unmet needs in metastatic hormone-sensitive prostate cancer (mHSPC).

Moving the novel hormonal therapies to the up-front setting in prostate cancer has resulted in improved survival by 1 to 3 years, says Agarwal. However, patients are likely to experience disease progression after these therapies. These patients who progress on hormonal therapies have a particularly challenging disease subtype to treat.

Additionally, although the majority of patients with mHSPC will respond to hormonal therapies, about 10% to 15% of patients will experience early disease progression, Agarwal explains. Moreover, the average survival for these short-term responders is around 2 years following the onset of metastatic castration-naïve prostate cancer. Future research efforts should determine the optimal course of treatment for these patients and whether treatment intensification could provide added benefit, concludes Agarwal.

Related Videos
Omid Hamid, MD
Marlana M. Orloff, MD
Mark Faries, MD
6368672538112
Dr Jabbour on Bleximenib Monotherapy in KMT2A+ or NPM1+ R/R Acute Leukemia
Julie Lang, MD, discusses real-world outcomes of the neoadjuvant KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer.
Rene Y. McNall-Knapp, MD, pediatric hematologist-oncologist, Jimmy Everest Center, Oklahoma Children’s Hospital OU Health; professor, Department of Pediatrics, University of Oklahoma Health Sciences Center
John Andrew Livingston, MD, MS
Howard Colman, MD, PhD, Jan M. Huntsman Presidential Professor, Department of Neurosurgery, member, Brain Tumor Research Team, and leader, Center for Neurologic Cancers, Huntsman Cancer Institute, University of Utah
Kathleen N. Moore, MD, MS